FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912497184> ?p ?o ?g. }

• W2912497184 endingPage "711" @default.
• W2912497184 startingPage "701" @default.
• W2912497184 abstract "IntroductionThis phase II study evaluated the efficacy and safety of the pan-cyclin–dependent kinase inhibitor roniciclib with platinum-based chemotherapy in patients with extensive-disease SCLC.MethodsIn this randomized, double-blind study, unselected patients with previously untreated extensive-disease SCLC received roniciclib, 5 mg, or placebo twice daily according to a 3 days–on, 4 days–off schedule in 21-day cycles, with concomitant cisplatin or carboplatin on day 1 and etoposide on days 1 to 3. The primary end point was progression-free survival. Other end points included overall survival, objective response rate, and safety.ResultsA total of 140 patients received treatment: 70 with roniciclib plus chemotherapy and 70 with placebo plus chemotherapy. Median progression-free survival times was 4.9 months (95% confidence interval [CI]: 4.2–5.5) with roniciclib plus chemotherapy and 5.5 months (95% CI: 4.6–5.6) with placebo plus chemotherapy (hazard ratio [HR] = 1.242, 95% CI: 0.820–1.881, p = 0.8653). Median overall survival times was 9.7 months (95% CI: 7.9–11.1) with roniciclib plus chemotherapy and 10.3 months (95% CI: 8.7–11.9) with placebo plus chemotherapy (HR = 1.281, 95% CI: 0.776–1.912, p = 0.7858). The objective response rates were 60.6% with roniciclib plus chemotherapy and 74.6% with placebo plus chemotherapy. Common treatment-emergent adverse events in both groups included nausea, vomiting, and fatigue. Serious treatment-emergent adverse events were more common with roniciclib plus chemotherapy (57.1%) than with placebo plus chemotherapy (38.6%).ConclusionsRoniciclib combined with chemotherapy demonstrated an unfavorable risk-benefit profile in patients with extensive-disease SCLC, and the study was prematurely terminated." @default.
• W2912497184 created "2019-02-21" @default.
• W2912497184 creator A5001428569 @default.
• W2912497184 creator A5031109105 @default.
• W2912497184 creator A5033220886 @default.
• W2912497184 creator A5043433926 @default.
• W2912497184 creator A5060572768 @default.
• W2912497184 creator A5062894702 @default.
• W2912497184 creator A5066661309 @default.
• W2912497184 creator A5068824818 @default.
• W2912497184 creator A5069371930 @default.
• W2912497184 creator A5070782948 @default.
• W2912497184 creator A5080158579 @default.
• W2912497184 creator A5082798685 @default.
• W2912497184 creator A5087836238 @default.
• W2912497184 creator A5089891961 @default.
• W2912497184 creator A5090624781 @default.
• W2912497184 date "2019-04-01" @default.
• W2912497184 modified "2023-10-16" @default.
• W2912497184 title "Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer" @default.
• W2912497184 cites W1979491540 @default.
• W2912497184 cites W1995038735 @default.
• W2912497184 cites W2020917220 @default.
• W2912497184 cites W2046024621 @default.
• W2912497184 cites W2086451010 @default.
• W2912497184 cites W2089744178 @default.
• W2912497184 cites W2101156795 @default.
• W2912497184 cites W2120277401 @default.
• W2912497184 cites W2150878803 @default.
• W2912497184 cites W2158127925 @default.
• W2912497184 cites W2165395478 @default.
• W2912497184 cites W2169848988 @default.
• W2912497184 cites W2189238890 @default.
• W2912497184 cites W2583136106 @default.
• W2912497184 cites W2611326266 @default.
• W2912497184 cites W2754274368 @default.
• W2912497184 cites W2765782352 @default.
• W2912497184 cites W2799790020 @default.
• W2912497184 cites W2893960509 @default.
• W2912497184 doi "https://doi.org/10.1016/j.jtho.2019.01.010" @default.
• W2912497184 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30677506" @default.
• W2912497184 hasPublicationYear "2019" @default.
• W2912497184 type Work @default.
• W2912497184 sameAs 2912497184 @default.
• W2912497184 citedByCount "36" @default.
• W2912497184 countsByYear W29124971842019 @default.
• W2912497184 countsByYear W29124971842020 @default.
• W2912497184 countsByYear W29124971842021 @default.
• W2912497184 countsByYear W29124971842022 @default.
• W2912497184 countsByYear W29124971842023 @default.
• W2912497184 crossrefType "journal-article" @default.
• W2912497184 hasAuthorship W2912497184A5001428569 @default.
• W2912497184 hasAuthorship W2912497184A5031109105 @default.
• W2912497184 hasAuthorship W2912497184A5033220886 @default.
• W2912497184 hasAuthorship W2912497184A5043433926 @default.
• W2912497184 hasAuthorship W2912497184A5060572768 @default.
• W2912497184 hasAuthorship W2912497184A5062894702 @default.
• W2912497184 hasAuthorship W2912497184A5066661309 @default.
• W2912497184 hasAuthorship W2912497184A5068824818 @default.
• W2912497184 hasAuthorship W2912497184A5069371930 @default.
• W2912497184 hasAuthorship W2912497184A5070782948 @default.
• W2912497184 hasAuthorship W2912497184A5080158579 @default.
• W2912497184 hasAuthorship W2912497184A5082798685 @default.
• W2912497184 hasAuthorship W2912497184A5087836238 @default.
• W2912497184 hasAuthorship W2912497184A5089891961 @default.
• W2912497184 hasAuthorship W2912497184A5090624781 @default.
• W2912497184 hasBestOaLocation W29124971841 @default.
• W2912497184 hasConcept C126322002 @default.
• W2912497184 hasConcept C141071460 @default.
• W2912497184 hasConcept C142724271 @default.
• W2912497184 hasConcept C143998085 @default.
• W2912497184 hasConcept C197934379 @default.
• W2912497184 hasConcept C204787440 @default.
• W2912497184 hasConcept C207103383 @default.
• W2912497184 hasConcept C27081682 @default.
• W2912497184 hasConcept C2776256026 @default.
• W2912497184 hasConcept C2776694085 @default.
• W2912497184 hasConcept C2778119113 @default.
• W2912497184 hasConcept C2778239845 @default.
• W2912497184 hasConcept C2780580376 @default.
• W2912497184 hasConcept C2781451048 @default.
• W2912497184 hasConcept C44249647 @default.
• W2912497184 hasConcept C71924100 @default.
• W2912497184 hasConcept C90924648 @default.
• W2912497184 hasConceptScore W2912497184C126322002 @default.
• W2912497184 hasConceptScore W2912497184C141071460 @default.
• W2912497184 hasConceptScore W2912497184C142724271 @default.
• W2912497184 hasConceptScore W2912497184C143998085 @default.
• W2912497184 hasConceptScore W2912497184C197934379 @default.
• W2912497184 hasConceptScore W2912497184C204787440 @default.
• W2912497184 hasConceptScore W2912497184C207103383 @default.
• W2912497184 hasConceptScore W2912497184C27081682 @default.
• W2912497184 hasConceptScore W2912497184C2776256026 @default.
• W2912497184 hasConceptScore W2912497184C2776694085 @default.
• W2912497184 hasConceptScore W2912497184C2778119113 @default.
• W2912497184 hasConceptScore W2912497184C2778239845 @default.
• W2912497184 hasConceptScore W2912497184C2780580376 @default.
• W2912497184 hasConceptScore W2912497184C2781451048 @default.

• next